New Hope For Esophageal Cancer Patients — Immunotherapy Opdivo Approved For Treatment Of Advanced Esophageal Cancer

Published Jun 18, 2020

New Hope For Esophageal Cancer Patients — Immunotherapy Opdivo Approved For Treatment Of Advanced Esophageal Cancer

Checkpoint inhibitor OPDIVO has shown tremendous promise for patients battling advanced esophageal cancer. An expert tells SurvivorNet that in esophageal cancer, anything that improves survival in patients whose disease already progresses after chemotherapy is remarkable.

NOW
PLAYING
Using CAR T-Cell Therapy Earlier
NOW
PLAYING
CART T-Cell Therapy During the COVID-19 Pandemic: Is it Safe?
NOW
PLAYING
New Hope For Stomach Cancer: Immunotherapy Drug Opdivo Now Approved As a First Treatment
NOW
PLAYING
All About Acute Lymphoblastic Leukemia
NOW
PLAYING
A New Option for Some People With Lung Cancer: How This Immunotherapy/Chemotherapy Combo Can Increase Treatment Success
NOW
PLAYING
Some Melanoma Survivors See Long-Term Side Effects After Immunotherapy, Says New Study

SurvivorNetTV.
Hope. Science.
Inspiration.

WATCH NOW
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.